Quick Answer
ZyVersa Therapeutics, Inc. reported Cash And Cash Equivalents At Carrying Value of $928.4 thousand for the year ending 2021.
- This data is from ZyVersa Therapeutics, Inc.'s annual report (Form 10-K), filed with the SEC on April 15, 2022.
- XBRL data for this metric is available from 2021 to 2021 (1 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q4 2021: $928.4 thousand | Q1 2022: $830.2 thousand | Q2 2022: $340.0 thousand | Q3 2022: $213.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: